# Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct07752550/  
OnCo record `nct07752550` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of retlirafusp alfa, nab-paclitaxel and fluzoparib in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting.

## Summary

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07752550 by Harbin Medical University, with a registry enrolment figure of 120 participants, started 2026-07-30 and due to reach its primary completion in 2028-07-30. Interventions recorded: Retlirafusp alfa+Nab-paclitaxel:; Retlirafusp alfa+Fluzoparib; Retlirafusp alfa+TP-AC; Retlirafusp alfa+Fluzoparib. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Histopathologically confirmed recurrent or metastatic triple-negative breast cancer, defined as ER-negative (IHC ER-positive percentage \<1%), PR-negative (IHC PR-positive percentage \<1%), and HER2-negative (IHC -/+ or IHC ++ but FISH/CISH -);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07752550
- Phase: 2
- Setting: Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study
- Sponsor: Harbin Medical University
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07752550: https://clinicaltrials.gov/study/NCT07752550

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Fluzoparib](https://onco.cc/drugs/fluzoparib/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Retlirafusp alfa](https://onco.cc/drugs/retlirafusp-alfa/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07752550.json